Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback